Beam Therapeutics Inc.

BEAM · Nasdaq · United States

Share price · BEAM

$21.01-5.56 (-20.93%) 3M

close as of 2026-11-18 · 24h delayed · vol 4.9M (2.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BEAM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 28 Oct 2026+15.6%
  2. 8 Sep 2026-9.5%
  3. 25 Aug 2026+9.5%
  4. 4 Aug 2026+9.4%
  5. 23 Jun 2026-6.6%

    Nothing announced by BEAM that day or the session before.

  6. 4 Jun 2026+11.1%

    Nothing announced by BEAM that day or the session before.

  7. 6 May 2026+11.9%

    Nothing announced by BEAM that day or the session before.

  8. 27 Apr 2026+7.6%

    Nothing announced by BEAM that day or the session before.

  9. 24 Apr 2026-10.1%

    Nothing announced by BEAM that day or the session before.

  10. 13 Apr 2026+10.0%

    Nothing announced by BEAM that day or the session before.

Share of unusual movement by asset

For each asset, the share of BEAM's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Ristoglogene autogetemcel
events and moves
1shown from 8 days
BEAM-302
events and moves
1shown from 8 days
BEAM-301
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—7%
Other company news (earnings, financing, releases naming no asset)—21%
Sessions with no dated event—72%

Assets

(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 1/2
G6PC1 (glucose-6-phosphatase-alpha) R83C variantGene therapy / editing
Glycogen Storage Disease Type Ia
Phase 1/2
SERPINA1 PiZ mutation (E342K)Gene therapy / editing
Alpha-1 Antitrypsin Deficiency
Phase 1/2
HBG1/HBG2 promotersGene therapy / editing
Sickle Cell Disease
Preclinical / Unstaged
PAH gene (phenylalanine hydroxylase)Gene therapy / editing
Phenylketonuria

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
BEAM-301Phase 1/2Glycogen Storage Disease Type Ia
Est. primary completion 2027-12-30 · NCT06735755 · CT.gov ↗
What to watch
2028 (2)
February 2028 (1)
Ristoglogene autogetemcelPhase 1/2Sickle Cell Disease
Est. primary completion 2028-02 · NCT05456880 · CT.gov ↗
What to watch
May 2028 (1)
BEAM-302Phase 1/2Alpha 1-Antitrypsin Deficiency
Est. primary completion 2028-05 · NCT06389877 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

10 November 2026Topline resultRistoglogene autogetemcelBEACON meets its primary efficacy endpoint
Beam Therapeutics Inc. · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.3M$110M$220M+ $831M short-term inv.$134M-$111M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0.5M$95M$227M+ $933M short-term inv.$123M-$66M operating cash flowreport ↗
2026-Q1$32M$105M$295M+ $923M short-term inv.$94M-$129M operating cash flowreport ↗
2025-Q3$9.7M$110M$275M+ $807M short-term inv.$113M-$81M operating cash flowreport ↗
2025-Q2$8.5M$102M$289M+ $868M short-term inv.$102M-$76M operating cash flowreport ↗
2025-Q1$7.5M$99M$535M+ $692M short-term inv.$109M-$104M operating cash flowreport ↗
2024-Q3$14M$94M$237M+ $696M short-term inv.$97M-$88M operating cash flowreport ↗
2024-Q2$12M$87M$299M+ $715M short-term inv.$91M-$83M operating cash flowreport ↗
2024-Q1$7.4M$85M$294M+ $807M short-term inv.$99M-$100M operating cash flowreport ↗
2023-Q3$17M$100M$178M+ $846M short-term inv.$96M-$90M operating cash flowreport ↗
2023-Q2$20M$98M$241M+ $847M short-term inv.$83M-$85M operating cash flowreport ↗
2023-Q1$24M$100M$260M+ $810M short-term inv.$96M-$110M operating cash flowreport ↗
2022-Q3$16M$85M$169M+ $943M short-term inv.$110M-$75M operating cash flowreport ↗
2022-Q2$17M$75M$278M+ $934M short-term inv.$72M-$52M operating cash flowreport ↗
2022-Q1$8.4M$65M$310M+ $903M short-term inv.$69M$218M operating cash flowreport ↗
2021-Q3$0.8M$55M$627M+ $321M short-term inv.$28M$3.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$140M$410M$302M+ $950M short-term inv.$20M-$345M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$64M$368M$290M+ $569M short-term inv.$94M-$347M operating cash flowreport ↗
2023-FY$378M$437M$445M+ $754M short-term inv.$33M-$149M operating cash flowreport ↗
2022-FY$61M$312M$246M+ $845M short-term inv.$72M$23M operating cash flowreport ↗
2021-FY$52M$387M$573M+ $406M short-term inv.$93M-$66M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 31 sales ($19.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2033-06-06Walsh Kathleen E · directorAward / grant (derivative)16,532——Form 4
2026-10-16Evans John M. · director, CEOOption exercise25,000$1.03$26KForm 4
2026-10-16Evans John M. · director, CEOOpen-market sale25,000$23.98$600KForm 4
2026-10-16Evans John M. · director, CEOOption exercise (derivative)25,000——Form 4
2026-10-15Evans John M. · director, CEOOption exercise25,000$1.03$26KForm 4
2026-10-15Evans John M. · director, CEOOpen-market sale25,000$23.57$589KForm 4
2026-10-15Evans John M. · director, CEOOption exercise (derivative)25,000——Form 4
2026-10-01Cavanagh Bethany J · SVP, Finance and TreasurerOpen-market sale187$24.41$5KForm 4